BRIEF

on PREDILIFE (EPA:ALPRE)

Valorization of the MammoRisk® software by PREDILIFE

PREDILIFE, specialist in artificial intelligence methods for predicting pathologies, announced the valorization of its MammoRisk® software. The SORGEM Evaluation firm was mandated for this evaluation, led by Madame Blanche Feauveaux.

MammoRisk® software is used in an EU-supported clinical study to compare stratified and standard breast cancer screening. This system could influence future screening recommendations. The value of MammoRisk® is estimated between 191.7 million and 223.3 million euros.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all PREDILIFE news